Table 3 Comparison of the economic and clinical outcomes according to carbapenem susceptibility of infecting organism
Variables | CS infections (N = 9431) | CR infections (N = 86) | P-value |
|---|---|---|---|
Death, n (%) | 2062 (21.9) | 22 (25.6) | 0.407 |
Length of hospital stay (days), median (IQR) | |||
 Total | 46 (29–74) | 64 (39–99) |  < 0.001 |
 Before culture test | 13 (6–25) | 24 (10–57) |  < 0.001 |
 After culture test | 27 (15–50) | 30 (16–67) | 0.132 |
Cost (USD), median (IQR) | Â | Â | |
 Total | 20,077 (12,670–33,345) | 27,501 (17,186–48,980) |  < 0.001 |
 Inter-consultations | 143 (80–244) | 163 (96–312) | 0.238 |
 Medications | 1609 (736–3,571) | 3477 (1585–9716) |  < 0.001 |
 Surgical procedures | 2327 (362–9,377) | 3761 (572–12,239) | 0.196 |
 Laboratory tests | 1845 (1185–2930) | 2498 (1666–4640) | 0.002 |
 Hospital stay | 10,560 (6789–16,304) | 14,307 (9790–22,471) |  < 0.001 |